Seres Therapeutics to Host Second Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on August 3, 2022

Rhea-AI Summary

Seres Therapeutics, Inc. (Nasdaq: MCRB) will host a conference call on August 3, 2022 at 8:30 a.m. ET to discuss its second quarter results and provide a business update.

Seres is noted for its SER-109 program, which has achieved significant clinical results in targeting C. difficile infections, receiving both Breakthrough Therapy and Orphan Drug designations from the FDA. The company is also advancing its SER-155 program to reduce infections in patients undergoing stem cell transplants.

Positive

• SER-109 achieved first-ever positive pivotal clinical results for a microbiome drug candidate.
• SER-109 received Breakthrough Therapy and Orphan Drug designations from the FDA.
• Ongoing Phase 1b study for SER-155 targeting gastrointestinal infections.

Negative

• None.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on August 3, 2022, at 8:30 a.m. ET to discuss second quarter 2022 results and provide a general business update.

To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference conference ID 3171491. To join the live webcast, please visit the “Investors and News” section of the Seres website at www.serestherapeutics.com.

A webcast replay will be available on the Seres website beginning approximately two hours after the event and will be archived for approximately 21 days.

About Seres Therapeutics

Seres Therapeutics, Inc. (Nasdaq: MCRB) is a leading microbiome therapeutics company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres’ SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SER-109 program is being advanced to prevent further recurrences of C. difficile infection and has potential to become a first-in-class FDA-approved microbiome therapeutic. Seres is evaluating SER-155 in a Phase 1b study in patients receiving allogeneic hematopoietic stem cell transplantation to reduce incidences of gastrointestinal infections, bloodstream infections and graft-versus-host disease as well as additional preclinical stage programs targeting Infection Protection in medically compromised patients. The Company is also conducting research to inform further development of microbiome therapeutics for ulcerative colitis.

For more information, please visit www.serestherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220728005127/en/

PR

Kristin Ainsworth

kainsworth@serestherapeutics.com

IR

Carlo Tanzi, Ph.D.

ctanzi@serestherapeutics.com

Source: Seres Therapeutics, Inc.

FAQ

What are the details of Seres Therapeutics' August 2022 conference call?

Seres Therapeutics will hold a conference call on August 3, 2022, at 8:30 a.m. ET to discuss second quarter results.

What is the significance of the SER-109 program for Seres Therapeutics and MCRB stock?

The SER-109 program is notable for achieving positive pivotal clinical results and receiving FDA designations, which may impact MCRB's stock price positively.

What is the focus of the SER-155 program at Seres Therapeutics?

The SER-155 program aims to reduce gastrointestinal infections and complications in patients receiving stem cell transplants.